How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
67
FULC Quote, Financials, Valuation and Earnings
Last price:
$10.49
Seasonality move
:
-23.08%
Day range:
$10.48 - $11.11
52-week range:
$2.32 - $15.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.92x
Volume:
496.9K
Avg. volume:
802K
1-year change:
170.71%
Market cap:
$580.1M
Revenue:
$80M
EPS (TTM):
-$1.18
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
FULC
Fulcrum Therapeutics, Inc.
|
-- | -$0.30 | -100% | -1.73% | $19.10 |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$12.1M | -$1.95 | 80.51% | -19.53% | $36.75 |
|
APLS
Apellis Pharmaceuticals, Inc.
|
$199.3M | -$0.40 | 15.96% | -35.89% | $33.95 |
|
BIIB
Biogen, Inc.
|
$2.2B | $1.63 | -2.75% | 111.55% | $193.00 |
|
CRMD
CorMedix, Inc.
|
$127M | $0.80 | 178.34% | 90.44% | $14.86 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
FULC
Fulcrum Therapeutics, Inc.
|
$10.72 | $19.10 | $580.1M | -- | $0.00 | 0% | -- |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$28.16 | $36.75 | $1.6B | 3.91x | $0.00 | 0% | 36.26x |
|
APLS
Apellis Pharmaceuticals, Inc.
|
$22.83 | $33.95 | $2.9B | 76.87x | $0.00 | 0% | 2.84x |
|
BIIB
Biogen, Inc.
|
$179.09 | $193.00 | $26.3B | 16.33x | $0.00 | 0% | 2.71x |
|
CRMD
CorMedix, Inc.
|
$8.17 | $14.86 | $643.7M | 3.98x | $0.00 | 0% | 2.75x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.71 | $0.85 | $215.8M | 2.87x | $0.80 | 0% | 3.32x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
FULC
Fulcrum Therapeutics, Inc.
|
3.41% | 4.992 | 1.41% | 17.25x |
|
AGIO
Agios Pharmaceuticals, Inc.
|
3.35% | 2.234 | 1.9% | 12.81x |
|
APLS
Apellis Pharmaceuticals, Inc.
|
54.23% | 0.668 | 16.61% | 2.96x |
|
BIIB
Biogen, Inc.
|
26.58% | 0.777 | 32.07% | 1.77x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.679 | 0.48% | 1.60x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -2.840 | 8.08% | 1.85x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
FULC
Fulcrum Therapeutics, Inc.
|
-$300K | -$21.9M | -30.08% | -31.15% | 65.62% | -$14.3M |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$9.8M | -$116.9M | -26.57% | -27.53% | -907.37% | -$89.7M |
|
APLS
Apellis Pharmaceuticals, Inc.
|
$433.7M | $223.2M | 6.35% | 18.94% | 48.67% | $108.3M |
|
BIIB
Biogen, Inc.
|
$1.6B | $613.8M | 6.76% | 9.36% | 25% | $1.2B |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
Fulcrum Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns FULC or AGIO?
Agios Pharmaceuticals, Inc. has a net margin of 69.26% compared to Fulcrum Therapeutics, Inc.'s net margin of -803.05%. Fulcrum Therapeutics, Inc.'s return on equity of -31.15% beat Agios Pharmaceuticals, Inc.'s return on equity of -27.53%.
Company Gross Margin Earnings Per Share Invested Capital FULCFulcrum Therapeutics, Inc.-- -$0.31 $205.4M AGIOAgios Pharmaceuticals, Inc.76.3% -$1.78 $1.3B -
What do Analysts Say About FULC or AGIO?
Fulcrum Therapeutics, Inc. has a consensus price target of $19.10, signalling upside risk potential of 78.17%. On the other hand Agios Pharmaceuticals, Inc. has an analysts' consensus of $36.75 which suggests that it could grow by 30.5%. Given that Fulcrum Therapeutics, Inc. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe Fulcrum Therapeutics, Inc. is more attractive than Agios Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FULCFulcrum Therapeutics, Inc.6 1 0 AGIOAgios Pharmaceuticals, Inc.7 3 0 -
Is FULC or AGIO More Risky?
Fulcrum Therapeutics, Inc. has a beta of 3.189, which suggesting that the stock is 218.879% more volatile than S&P 500. In comparison Agios Pharmaceuticals, Inc. has a beta of 0.915, suggesting its less volatile than the S&P 500 by 8.508%.
-
Which is a Better Dividend Stock FULC or AGIO?
Fulcrum Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agios Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulcrum Therapeutics, Inc. pays -- of its earnings as a dividend. Agios Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FULC or AGIO?
Fulcrum Therapeutics, Inc. quarterly revenues are --, which are smaller than Agios Pharmaceuticals, Inc. quarterly revenues of $12.9M. Fulcrum Therapeutics, Inc.'s net income of -$19.6M is higher than Agios Pharmaceuticals, Inc.'s net income of -$103.4M. Notably, Fulcrum Therapeutics, Inc.'s price-to-earnings ratio is -- while Agios Pharmaceuticals, Inc.'s PE ratio is 3.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulcrum Therapeutics, Inc. is -- versus 36.26x for Agios Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FULCFulcrum Therapeutics, Inc.-- -- -- -$19.6M AGIOAgios Pharmaceuticals, Inc.36.26x 3.91x $12.9M -$103.4M
-
Which has Higher Returns FULC or APLS?
Apellis Pharmaceuticals, Inc. has a net margin of 69.26% compared to Fulcrum Therapeutics, Inc.'s net margin of 47.04%. Fulcrum Therapeutics, Inc.'s return on equity of -31.15% beat Apellis Pharmaceuticals, Inc.'s return on equity of 18.94%.
Company Gross Margin Earnings Per Share Invested Capital FULCFulcrum Therapeutics, Inc.-- -$0.31 $205.4M APLSApellis Pharmaceuticals, Inc.94.58% $1.66 $876.5M -
What do Analysts Say About FULC or APLS?
Fulcrum Therapeutics, Inc. has a consensus price target of $19.10, signalling upside risk potential of 78.17%. On the other hand Apellis Pharmaceuticals, Inc. has an analysts' consensus of $33.95 which suggests that it could grow by 48.7%. Given that Fulcrum Therapeutics, Inc. has higher upside potential than Apellis Pharmaceuticals, Inc., analysts believe Fulcrum Therapeutics, Inc. is more attractive than Apellis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FULCFulcrum Therapeutics, Inc.6 1 0 APLSApellis Pharmaceuticals, Inc.11 7 1 -
Is FULC or APLS More Risky?
Fulcrum Therapeutics, Inc. has a beta of 3.189, which suggesting that the stock is 218.879% more volatile than S&P 500. In comparison Apellis Pharmaceuticals, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.354%.
-
Which is a Better Dividend Stock FULC or APLS?
Fulcrum Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Apellis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulcrum Therapeutics, Inc. pays -- of its earnings as a dividend. Apellis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FULC or APLS?
Fulcrum Therapeutics, Inc. quarterly revenues are --, which are smaller than Apellis Pharmaceuticals, Inc. quarterly revenues of $458.6M. Fulcrum Therapeutics, Inc.'s net income of -$19.6M is lower than Apellis Pharmaceuticals, Inc.'s net income of $215.7M. Notably, Fulcrum Therapeutics, Inc.'s price-to-earnings ratio is -- while Apellis Pharmaceuticals, Inc.'s PE ratio is 76.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulcrum Therapeutics, Inc. is -- versus 2.84x for Apellis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FULCFulcrum Therapeutics, Inc.-- -- -- -$19.6M APLSApellis Pharmaceuticals, Inc.2.84x 76.87x $458.6M $215.7M
-
Which has Higher Returns FULC or BIIB?
Biogen, Inc. has a net margin of 69.26% compared to Fulcrum Therapeutics, Inc.'s net margin of 19%. Fulcrum Therapeutics, Inc.'s return on equity of -31.15% beat Biogen, Inc.'s return on equity of 9.36%.
Company Gross Margin Earnings Per Share Invested Capital FULCFulcrum Therapeutics, Inc.-- -$0.31 $205.4M BIIBBiogen, Inc.64.29% $3.17 $24.8B -
What do Analysts Say About FULC or BIIB?
Fulcrum Therapeutics, Inc. has a consensus price target of $19.10, signalling upside risk potential of 78.17%. On the other hand Biogen, Inc. has an analysts' consensus of $193.00 which suggests that it could grow by 7.77%. Given that Fulcrum Therapeutics, Inc. has higher upside potential than Biogen, Inc., analysts believe Fulcrum Therapeutics, Inc. is more attractive than Biogen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FULCFulcrum Therapeutics, Inc.6 1 0 BIIBBiogen, Inc.14 18 1 -
Is FULC or BIIB More Risky?
Fulcrum Therapeutics, Inc. has a beta of 3.189, which suggesting that the stock is 218.879% more volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.160, suggesting its less volatile than the S&P 500 by 84.033%.
-
Which is a Better Dividend Stock FULC or BIIB?
Fulcrum Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulcrum Therapeutics, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FULC or BIIB?
Fulcrum Therapeutics, Inc. quarterly revenues are --, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. Fulcrum Therapeutics, Inc.'s net income of -$19.6M is lower than Biogen, Inc.'s net income of $466.5M. Notably, Fulcrum Therapeutics, Inc.'s price-to-earnings ratio is -- while Biogen, Inc.'s PE ratio is 16.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulcrum Therapeutics, Inc. is -- versus 2.71x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FULCFulcrum Therapeutics, Inc.-- -- -- -$19.6M BIIBBiogen, Inc.2.71x 16.33x $2.5B $466.5M
-
Which has Higher Returns FULC or CRMD?
CorMedix, Inc. has a net margin of 69.26% compared to Fulcrum Therapeutics, Inc.'s net margin of 49.9%. Fulcrum Therapeutics, Inc.'s return on equity of -31.15% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital FULCFulcrum Therapeutics, Inc.-- -$0.31 $205.4M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About FULC or CRMD?
Fulcrum Therapeutics, Inc. has a consensus price target of $19.10, signalling upside risk potential of 78.17%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 81.85%. Given that CorMedix, Inc. has higher upside potential than Fulcrum Therapeutics, Inc., analysts believe CorMedix, Inc. is more attractive than Fulcrum Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FULCFulcrum Therapeutics, Inc.6 1 0 CRMDCorMedix, Inc.4 0 0 -
Is FULC or CRMD More Risky?
Fulcrum Therapeutics, Inc. has a beta of 3.189, which suggesting that the stock is 218.879% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.76%.
-
Which is a Better Dividend Stock FULC or CRMD?
Fulcrum Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulcrum Therapeutics, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FULC or CRMD?
Fulcrum Therapeutics, Inc. quarterly revenues are --, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Fulcrum Therapeutics, Inc.'s net income of -$19.6M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Fulcrum Therapeutics, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulcrum Therapeutics, Inc. is -- versus 2.75x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FULCFulcrum Therapeutics, Inc.-- -- -- -$19.6M CRMDCorMedix, Inc.2.75x 3.98x $104.3M $108.6M
-
Which has Higher Returns FULC or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of 69.26% compared to Fulcrum Therapeutics, Inc.'s net margin of -255.85%. Fulcrum Therapeutics, Inc.'s return on equity of -31.15% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital FULCFulcrum Therapeutics, Inc.-- -$0.31 $205.4M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About FULC or NBY?
Fulcrum Therapeutics, Inc. has a consensus price target of $19.10, signalling upside risk potential of 78.17%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -50.29%. Given that Fulcrum Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Fulcrum Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FULCFulcrum Therapeutics, Inc.6 1 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is FULC or NBY More Risky?
Fulcrum Therapeutics, Inc. has a beta of 3.189, which suggesting that the stock is 218.879% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.135, suggesting its less volatile than the S&P 500 by 86.499%.
-
Which is a Better Dividend Stock FULC or NBY?
Fulcrum Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Fulcrum Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FULC or NBY?
Fulcrum Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Fulcrum Therapeutics, Inc.'s net income of -$19.6M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Fulcrum Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulcrum Therapeutics, Inc. is -- versus 3.32x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FULCFulcrum Therapeutics, Inc.-- -- -- -$19.6M NBYNovaBay Pharmaceuticals, Inc.3.32x 2.87x $521K -$1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 43x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 43x
Alerts
Sell
49
HYMC alert for Feb 3
Hycroft Mining Holding Corp. [HYMC] is up 19.68% over the past day.
Buy
67
FBRX alert for Feb 3
Forte Biosciences, Inc. [FBRX] is down 0.2% over the past day.
Buy
72
BNR alert for Feb 3
Burning Rock Biotech Ltd. [BNR] is down 15.43% over the past day.
